Expanding Nilotinib Access In Clinical Trials (Enact) Study In Adult Patients (Pts) With Imatinib-Resistant Or -Intolerant Chronic Myeloid Leukemia (Cml) In Blast Crisis (Bc), Accelerated Phase (Ap), Or Chronic Phase (Cp): Preliminary Safety Analysis

Background: Nilotinib is a novel, oral ATP-competitive inhibitor of BCR-ABL; it is significantly more potent (>30-fold) and selective than imatinib. ENACT is an ongoing multicenter, open-label, expanded-access study for pts with imatinib-resistant/intolerant CML in all phases. The primary objective is to evaluate the safety of nilotinib in these pts.